US pharmaceutical giant Pfizer concluded its second sell-down in its consumer healthcare spin-off, Haleon. It raised £2.432bn ($3.25bn) by selling 43bn of shares in an accelerated bookbuild, which was ...

Oil prices jumped and stocks tumbled on Tuesday after Iran fired more than a hundred missiles at Israel in retaliation for ...

Following a similar move in March, Pfizer is offloading another tranche of Haleon shares. | Pfizer has sold 640 million ...

Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding ...

Haleon, a global leader in consumer health, today announced the appointment of Christine Jakovcic as General Manager, Haleon ...

The latest health news highlights include Kailera Therapeutics' $400 million funding, potential CVS Health restructuring, ...

Ford Motor Co said on Tuesday it will lower the annual and monthly subscription prices for its hands-free driving technology.

Pfizer (PFE) reduces its stake in Haleon to 15% from 22.6% by selling £2.45B worth of shares, continuing its gradual ...

Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding in the British consumer healthcare company.

Pfizer, a New York-based pharmaceuticals firm, sold 640 million Haleon shares at 380 pence per share in a placing run by Goldman Sachs International and BofA Securities as joint global coordinators.

Pfizer said, further to the Launch Announcement on 30 September 2024, it has sold 640 million ordinary shares in Haleon plc, at a ...

(Reuters) - Pfizer offloaded shares worth roughly $3.26 billion in Haleon at 380 pence apiece, cutting its stake to 15% in ...